UCSD Moores Cancer Center | Strategic Alliance Partners

Our unique blend of cancer research and patient care is transforming cancer prevention, detection and treatment. Established in 1978, Moores Cancer Center is the region’s only National Cancer Institute-designated Comprehensive Cancer Center. This designation is reserved for centers with the highest achievements in cancer research, clinical care, education and community contributions.

Latest from UCSD Moores Cancer Center


Dr. Mayadev on Atezolizumab Plus Chemoradiation in Locally Advanced Cervical Cancer

March 22, 2022

Jyoti Mayadev, MD, discusses the phase 1 NRG-GY017 trial evaluating atezolizumab given as an immune primer or concurrently with extended field chemoradiation in patients with locally advanced, node-positive cervical cancer.

Analysis of Genomic Alterations in Metastases Could Help Inform Treatment in RCC

March 10, 2022

Rana R. McKay, MD, discusses findings from a real-world study on genomic alterations of metastases in renal cell carcinoma, the rationale of the phase 3 COSMIC-313 trial in patients with previously untreated advanced or metastatic RCC, plus findings from the phase 1/2 COMRADE trial in patients with metastatic castration-resistant prostate cancer.

Dr. Choi on the Addition of Ublituximab to Ibrutinib in R/R CLL

February 16, 2022

Michael Choi, MD, discusses the results of the phase 3 GENUINE trial examining ublituximab in combination with ibrutinib vs ibrutinib alone in patients with relapsed/refractory chronic lymphocytic leukemia.

Emerging TKIs Shake Up the Treatment Landscape for EGFR Exon 20 Insertion+ NSCLC

February 08, 2022

Lyudmila Bazhenova, MD, explores key challenges faced with diagnosing and appropriately treating patients with non–small cell lung cancer that harbors EGFR exon 20 insertion mutations and provides insight into the second-line options that have recently garnered regulatory approval.

Making the Most of Molecular Testing in Breast Cancer

August 12, 2021

Drs. Brown and Kurzrock discuss the current and future applications of next-generation sequencing in breast cancer, the role of tissue-based testing in light of the growing role for liquid-based testing, and some of the emerging technologies that could overcome current barriers to biomarker testing.